Vedolizumab

Vedolizumab is administered through a needle placed in a vein (intravenous infusion) in your arm. It is administered to you over a period of about 30 minutes. Your healthcare practitioner will monitor you while and after the entyvio infusion for the adverse reactions in order to see if you have a reaction to the treatment.

Most common adverse reactions include fever, common cold, joint pain, nausea, headache, infections of the nose and throat, tiredness, flu, cough, bronchitis, back pain, rash, itching, throat pain, sinus infection, and pain in the extremities.

Discontinue vedolizumab injection in patients who do not show evidence of the therapeutic advantage by Week 14.

This drug is contraindicated in patients with serious/severe hypersensitivity reactions to it or any of its excipients (such as bronchospasm, dyspnea, urticaria, rash, increased heart rate, and flushing)

The drug vedolizumab 300 mg needs to be discontinued in patients with jaundice or other evidence of significant liver injury Due to the potential for increased risk of PML, concomitant use of vedolizumab 300 mg with natalizumab should be avoided. Caution needs to be implemented when administering this medicine to a nursing woman. It is not recommended to conceive a child while taking kynteles. I

In order to do so may harm your unborn baby. Safety as well as effectiveness of entyvio 300 mg in pediatric patients have not been specified/established.

Care should be exercised in the handling of Vedolizumab. Vedolizumab injections should not be opened or crushed. Unopened vials should be refrigerated at 2° to 8°C (36°-46°F). It should be retained in the original package in order to protect from light.